Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 501.00K | $ 424.00K | $ 477.00K | $ 931.00K | $ 20.99M |
| Gross Profit | $ 501.00K | $ 424.00K | $ 477.00K | $ 931.00K | $ 19.60M |
| Operating Income | $ -43.64M | $ -29.26M | $ -34.30M | $ -38.91M | $ 252.55M |
| EBITDA | $ -43.63M | $ -29.26M | $ -34.22M | $ -38.80M | $ -251.09M |
| Net Income | $ -39.83M | $ -28.45M | $ -23.21M | $ -73.33M | $ -255.57M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 61.52M | $ 93.25M | $ 30.91M | $ 42.25M | $ 58.59M |
| Total Assets | $ 66.91M | $ 97.69M | $ 40.76M | $ 67.05M | $ 93.74M |
| Total Debt | $ 99.00K | $ 214.00K | $ 0.00 | $ 349.00K | $ 34.78M |
| Net Debt | $ -19.83M | $ -30.41M | $ -30.91M | $ -41.90M | $ -22.78M |
| Total Liabilities | $ 14.82M | $ 8.95M | $ 9.56M | $ 18.41M | $ 56.25M |
| Stockholders' Equity | $ 52.09M | $ 88.73M | $ 31.20M | $ 48.64M | $ 37.49M |
| Cash Flow | |||||
| Free Cash Flow | $ -34.09M | $ -25.34M | $ -29.20M | $ -56.37M | $ -137.19M |
| Operating Cash Flow | $ -33.97M | $ -25.34M | $ -29.20M | $ -56.37M | $ -137.08M |
| Investing Cash Flow | $ 23.36M | $ -57.35M | $ 15.67M | $ 1.03M | $ 89.11M |
| Financing Cash Flow | $ -141.00K | $ 82.39M | $ 1.65M | $ 39.78M | $ 61.81M |